Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Immunotherapy (IMT) is now a core component of cancer treatment, however, many patients do not respond to these novel therapies. Investigating the resistance mechanisms behind this differential response is now a critical area of research. Immune-based therapies, particularly immune checkpoint inhibitors (ICI), rely on a robust infiltration of T-cells into the tumor microenvironment (TME) for an effective response. While early efforts relied on quantifying tumor infiltrating lymphocytes (TIL) in the TME, characterizing the functional quality and degree of TIL exhaustion correlates more strongly with ICI response. Even with sufficient TME infiltration, immune cells face a harsh metabolic environment that can significantly impair effector function. These tumor-mediated metabolic perturbations include hypoxia, oxidative stress, and metabolites of cellular energetics. Primarily through HIF-1-dependent processes, hypoxia invokes an immunosuppressive phenotype via altered molecular markers, immune cell trafficking, and angiogenesis. Additionally, oxidative stress can promote lipid peroxidation, ER stress, and Treg dysfunction, all associated with immune dysregulation. Finally, the metabolic byproducts of lipids, amino acids, glucose, and cellular energetics are associated with immunosuppression and ICI resistance. This review will explore these biochemical pathways linked to immune cell dysfunction in the TME and highlight potential adjunctive therapies to be used alongside current IMT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Further disruption of already dysfunctional vessels has been shown to increase intratumoral hypoxia; a vicious cycle that upregulates HIF-1α, exacerbating many of the resistant mechanisms already described [46].”
BackgroundOverall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744 · cited 1×
“Regardless, increasing evidence points to an equal if not more critical dependence on mitochondrial metabolism as compared to glycolysis in regards to tumor progression and immunosuppression [86].”
BackgroundFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723 · cited 1×
“Although immune checkpoint inhibitors (ICI) and other novel immune-based therapies have revolutionized the current treatment paradigm of many cancers, only a minority of patients show sustained response [3].”
BackgroundPembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046
Fundamentals of Cancer Metabolism
DeBerardinis, R. J., & Chandel, N. S. (2016) · Science Advances · doi:10.1126/sciadv.1600200 · Cited by 3,013 · cited 1×
“An increase in glycolytic flux has certainly been demonstrated in many cancers, although glycolysis alone is not sufficient for energy production or tumor progression [83].”
BackgroundNoman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166 · cited 1×
“Hypoxic conditions have been shown to further stimulate the immunosuppressive function of these cells; MDSC PD-L1 expression is also strongly upregulated in response to HIF-1α [28].”
BackgroundGray, L. H., Conger, A. D., Ebert, M., Hornsey, S., & Scott, O. C. A. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-312-638 · Cited by 2,158 · cited 1×
“The translational ramifications of tumor hypoxia were described in detail over 60 years ago, when it was discovered that hypoxic tumor cells became resistant to radiation therapy [7].”
BackgroundThe Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Matrix metalloproteinases as modulators of inflammation and innate immunity
Parks, W. C., Wilson, C. L., & López-Boado, Y. S. (2004) · Nature Reviews Immunology · doi:10.1038/nri1418 · Cited by 1,929 · cited 1×
“TAMs have also been associated with increased matrix metalloproteinase-7 (MMP-7) expression in hypoxic regions of the TME; MMP-7 inhibits tumor cell lysis via cleavage of the Fas ligand, a transmembrane protein involved in apoptosis [22,23].”
BackgroundL-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
Geiger, R., Rieckmann, J. C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T., Kogadeeva, M., Picotti, P., Meissner, F., Mann, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.031 · Cited by 1,775 · cited 1×
“As with glutamine, arginine has also been shown to be a necessary cofactor for T cell survival and anti-tumor activity [98].”
p53 Regulates Mitochondrial Respiration
Matoba, S., Kang, J.-G., Patino, W. D., Wragg, A., Boehm, M., Gavrilova, O., Hurley, P. J., Bunz, F., & Hwang, P. M. (2006) · Science · doi:10.1126/science.1126863 · Cited by 1,650 · cited 1×
“For example, in addition to studying the oncogenic PI3K/AKT pathway, loss of the p53 tumor suppressor has also been shown to increase the flux of glycolytic intermediates [87].”
BackgroundControl of TH17/Treg Balance by Hypoxia-Inducible Factor 1
Dang, E. V., Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.-R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.033 · Cited by 1,595
HIF transcription factors, inflammation, and immunity
Palazon, A., Goldrath, A. W., Nizet, V., & Johnson, R. S. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.008 · Cited by 1,195 · cited 1×
“HIF-1α forms a heterodimer with HIF-1β; this complex binds to the hypoxia-responsive element (HRE) to induce expression of an assortment of genes used for normal tissue adaptation to low oxygen levels but also the aforementioned immunosuppressive phenotype of the TME [13].”
BackgroundCorzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
Hegde, P. S., Karanikas, V., & Evers, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1507 · Cited by 1,000
Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J.-J., Kim, T. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30274-8 · Cited by 960 · cited 1×
“pembrolizumab alone did not show improved survival outcomes [104].”
BackgroundER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis
Cubillos-Ruiz, J. R., Silberman, P. C., Rutkowski, M. R., Chopra, S., Perales-Puchalt, A., Song, M., Zhang, S., Bettigole, S. E., Gupta, D., Holcomb, K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.025 · Cited by 933 · cited 2×
“analyzed tumor-infiltrating dendritic cells within ovarian tumors—elevated ROS levels led to increased lipid peroxidation, HNE generation, and resultant ER stress [79].”
BackgroundAn inhibitor of oxidative phosphorylation exploits cancer vulnerability
Molina, J. R., Sun, Y., Protopopova, M., Gera, S., Bandi, M., Bristow, C., McAfoos, T., Morlacchi, P., Ackroyd, J., Agip, A.-N. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0052-4 · Cited by 928 · cited 1×
“Additionally, as will be described below, the metabolism and energy production of aggressive tumors can shift towards a highly oxidative state leading to hypoxic conditions for the remainder of the TME [12].”
BackgroundCarr, E. L., Kelman, A., Wu, G. S., Gopaul, R., Senkevitch, E., Aghvanyan, A., Turay, A. M., & Frauwirth, K. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903586 · Cited by 830
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells
Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-0992 · Cited by 767 · cited 4×
“HIF-1α, activated under hypoxic conditions, has been shown to directly upregulate expression of PD-L1, a process that inhibits further T-cell activation and signaling upon contact with PD-1 [16].”
BackgroundInfluentialMaj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733 · cited 2×
“studied the role of oxidative stress-induced apoptotic Treg cells in the TME [81].”
BackgroundResultTherapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687 · cited 1×
“A host of agents have been discovered with incidental HIF-1α modulation; these include antisense oligonucleotides, the translational inhibitor and microtubule-targeting metabolite 2-methoxyestradiol (2ME2), heat shock protein inhibitors, histone deacetylase inhibitors, and even topotecan (a topoisomerase I inhibitor)…”
BackgroundSynergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608
Sonveaux, P., Copetti, T., De Saedeleer, C. J., Végran, F., Verrax, J., Kennedy, K. M., Moon, E. J., Dhup, S., Danhier, P., Frérart, F., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033418 · Cited by 536
Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Scharping, N. E., Menk, A. V., Whetstone, R. D., Zeng, X., & Delgoffe, G. M. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0103 · Cited by 520 · cited 2×
“Furthermore, the effects of hypoxia on CTL cytolytic capabilities have been mixed [35], although our work with antigen-specific T cells revealed lower IFN-γ levels and depressed cytolytic activity under acutely hypoxic conditions [36].”
MethodResultSelf-citationZhang, H., Lu, H., Xiang, L., Bullen, J. W., Zhang, C., Samanta, D., Gilkes, D. M., He, J., & Semenza, G. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520032112 · Cited by 420
Labadie, B. W., Bao, R., & Luke, J. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2882 · Cited by 413
Qiu, B., Ackerman, D., Sanchez, D. J., Li, B., Ochocki, J. D., Grazioli, A., Bobrovnikova-Marjon, E., Diehl, J. A., Keith, B., & Simon, M. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1507 · Cited by 394 · cited 1×
“Overall, higher lipid content in tumors has been associated with increased metastatic potential and resistance to chemotherapy [113,114].”
BackgroundMitchell, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Olszanski, A. J., Luke, J. J., Balmanoukian, A. S., Schmidt, E. V., Zhao, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9602 · Cited by 388
Baginska, J., Viry, E., Berchem, G., Poli, A., Noman, M. Z., van Moer, K., Medves, S., Zimmer, J., Oudin, A., Niclou, S. P., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304790110 · Cited by 344 · cited 1×
“Recent work has demonstrated that hypoxia, via a HIF-1α- and pSTAT3-dependent mechanism, upregulates this process leading to selective degradation of granzyme B and depressed cytolysis [38].”
BackgroundHIF Inhibitors: Status of Current Clinical Development
Fallah, J., & Rini, B. I. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0752-z · Cited by 308 · cited 1×
“In general, modulators of HIF-1 and its downstream elements have shown strong potential to reverse immunosuppressive factors in the TME; future clinical trials should be aimed at combinatory methods with ICI and other immune-based therapies (see Table 1) [70].”
BackgroundThe EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death
Pozzi, C., Cuomo, A., Spadoni, I., Magni, E., Silvola, A., Conte, A., Sigismund, S., Ravenda, P. S., Bonaldi, T., Zampino, M. G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4078 · Cited by 292 · cited 1×
“Furthermore, XBP1, a multimodal transcription factor associated with MHC II regulation along with the ER stress response was found to impede tumor immunogenic cell death in a colorectal cancer model [77].”
BackgroundTolaney, S. M., Boucher, Y., Duda, D. G., Martin, J. D., Seano, G., Ancukiewicz, M., Barry, W. T., Goel, S., Lahdenrata, J., Isakoff, S. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518808112 · Cited by 258 · cited 1×
“More recent investigations have sought to “normalize” the vasculature of the TME via transient VEGF blockade to stabilize the endothelium, increase oxygen and drug delivery, and reduce vascular permeability with associated metastatic potential [47].”
BackgroundDeng, J., Li, J., Sarde, A., Lines, J. L., Lee, Y.-C., Qian, D. C., Pechenick, D. A., Manivanh, R., Le Mercier, I., Lowrey, C. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0507 · Cited by 224 · cited 1×
“Another checkpoint found on myeloid derived suppressor cells (MDSC), V-Domain Ig Suppressor of T-Cell Activation (VISTA) was also shown to be upregulated in hypoxic regions of a colon cancer (CT26) model via HIF-1α [17].”
BackgroundBorad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7504 · Cited by 197 · cited 1×
“After early promise [62], a phase III clinical trial (MAESTRO) is now underway, studying the effects of the hypoxia prodrug evofosfamide with gemcitabine in patients with pancreatic adenocarcinoma [63].”
BackgroundMetabolic reprogramming of the tumour microenvironment
Xing, Y., Zhao, S., Zhou, B. P., & Mi, J. (2015) · The FEBS Journal · doi:10.1111/febs.13402 · Cited by 108 · cited 1×
“Indeed, several activating mutations within the PI3K-AKT-mTOR pathway are linked to higher glycolytic rates, yet the competitive advantage is likely tied to enhanced production of glycolytic intermediates rather than ATP generation [84].”
Background
Cited by
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape: foe or friend?
Kuo, C.-L., Ponneri Babuharisankar, A., Lin, Y.-C., Lien, H.-W., Lo, Y. K., Chou, H.-Y., Tangeda, V., Cheng, L.-C., Cheng, A. N., & Lee, A. Y.-L. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00859-2 · Cited by 351
Tumour burden and efficacy of immune-checkpoint inhibitors
Dall’Olio, F. G., Marabelle, A., Caramella, C., Garcia, C., Aldea, M., Chaput, N., Robert, C., & Besse, B. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00564-3 · Cited by 350
The Role of the Hypoxia-Related Unfolded Protein Response (UPR) in the Tumor Microenvironment
Bartoszewska, S., Collawn, J. F., & Bartoszewski, R. (2022) · Cancers · doi:10.3390/cancers14194870 · Cited by 43
Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors
Zhang, X., Li, H., Lv, X., Hu, L., Li, W., Zi, M., & He, Y. (2022) · Life · doi:10.3390/life12030409 · Cited by 18
“In murine sarcoma models, tumor-derived retinoic acid (RA) blocked monocyte differentiation into dendritic cells (DCs) within the TME to promote immune suppression, whilst blocking RA production in tumor cells or inhibiting RA signaling within the TME increased the percentage of immunostimulatory antigen-presenting ce…”
BackgroundInfluential
Metadata
- Authors
- Augustin, R. C., Delgoffe, G. M., & Najjar, Y. G.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-12-17
- Volume
- 12
- Issue
- 12
- Pages
- 3802
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3111998751
- Cited by
- 129
- References
- 39
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.